3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Diseases
1
Interventions
pembrolizumab
29
Cisplatin
19
Carboplatin
13
Cetuximab
12
Radiotherapy
10
Paclitaxel
9
Surveys and Questionnaires
8
Docetaxel
6
Radiotherapy, Intensity-Modulated
5
Surgical Procedures, Operative
4
Standard of Care
4
130-nm albumin-bound paclitaxel
4
dostarlimab
3
Therapeutics
3
Nivolumab
3
Fluorouracil
3
Cyclophosphamide
3
Chemoradiotherapy
3
Blood Specimen Collection
3
Albumin-Bound Paclitaxel
3
toripalimab
2
nimotuzumab
2
fludarabine
2
durvalumab
2
atezolizumab
2
abemaciclib
2
X-Rays
2
Taxes
2
Radiosurgery
2
Radiation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
STX-478
×
90 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled